H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C. Wainwright raised the firm’s price target on BioMarin to $60 from $55 with a Neutral rating on the shares. This sentiment was announced amid the acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), which the firm described as a move that stabilizes long-term cash flows, though H.C. Wainwright also noted that peak sales won’t materialize until the 2030s. Therefore, Voxzogo will remain the primary driver of BioMarin’s stock value in the interim.

On December 19, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Amicus Therapeutics announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction valued at ~$4.8 billion. Under the terms of the deal, BioMarin will pay $14.50 per share. The Boards of Directors of both companies have unanimously approved the merger, which is expected to close in Q2 2026, pending regulatory clearances and Amicus stockholder approval.

The acquisition strategically expands BioMarin’s leadership in rare diseases by adding two high-growth, marketed therapies for lysosomal storage disorders. These include Galafold (migalastat), the first oral treatment for Fabry disease, and Pombiliti + Opfolda, a two-component therapy for Pompe disease. Over the last four quarters, these products generated a combined $599 million in revenue. Additionally, the deal includes US rights to DMX-200, a Phase 3 investigational small molecule targeting focal segmental glomerulosclerosis/FSGS, which is a rare kidney disease.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions in the US, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.